{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:36:20Z","timestamp":1789605380010,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/jhh.2015.59","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T09:21:37Z","timestamp":1433409697000},"page":"424-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension"],"prefix":"10.1038","volume":"30","author":[{"given":"H","family":"Yavuzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yavuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"R\u0131za Alt\u0131parmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Korkmazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Balci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Yald\u0131ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"BFjhh201559_CR1","first-page":"152","volume":"15","author":"C Savoia","year":"2006","unstructured":"Savoia C, Schiffrin EL . Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 152\u2013158.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFjhh201559_CR2","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.2337\/dc08-s246","volume":"31","author":"E Grossman","year":"2008","unstructured":"Grossman E . Does increased oxidative stress cause hypertension? Diabetes Care 2008; 31: S185\u2013S189.","journal-title":"Diabetes Care"},{"key":"BFjhh201559_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jama.1988.03720020027031","volume":"259","author":"TG Pickering","year":"1988","unstructured":"Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH . How common is white coat hypertension? JAMA 1988; 259: 225\u2013228.","journal-title":"JAMA"},{"key":"BFjhh201559_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/hh2101.099270","volume":"89","author":"GJ Blake","year":"2001","unstructured":"Blake GJ, Ridker PM . Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763\u2013771.","journal-title":"Circ Res"},{"key":"BFjhh201559_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH . Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731\u2013733.","journal-title":"Circulation"},{"key":"BFjhh201559_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1536\/ihj.13-253","volume":"55","author":"T Yasunaga","year":"2014","unstructured":"Yasunaga T, Ikeda S, Koga S, Nakata T, Yoshida T, Masuda N et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J 2014; 55: 160\u2013164.","journal-title":"Int Heart J"},{"key":"BFjhh201559_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1189\/jlb.1005557","volume":"79","author":"B Bottazzi","year":"2006","unstructured":"Bottazzi B, Bastone A, Doni A, Garlanda C, Valentino S, Deban L et al. The long pentraxin PTX3 as a link among innate immunity, inflamat\u0131on and female fertility. J Leukoc Biol 2006; 79: 909\u2013912.","journal-title":"J Leukoc Biol"},{"key":"BFjhh201559_CR8","first-page":"1605","volume":"79","author":"P Dandona","year":"1994","unstructured":"Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605\u20131608.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFjhh201559_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1253\/circj.CJ-10-0638","volume":"75","author":"CR Sinning","year":"2011","unstructured":"Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS et al. AtheroGene Study Investigators. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 2011; 75: 1184\u20131191.","journal-title":"Circ J"},{"key":"BFjhh201559_CR10","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/HJH.0b013e328360ddd5","volume":"31","author":"F Mallamaci","year":"2013","unstructured":"Mallamaci F, Leonardis D, Pizzini P, Cutrupi S, Tripepi G, Zoccali C . Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. J Hypertens 2013; 31: 1424\u20131430.","journal-title":"J Hypertens"},{"key":"BFjhh201559_CR11","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1161\/ATVBAHA.111.231431","volume":"31","author":"S Demyanets","year":"2011","unstructured":"Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080\u20132089.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFjhh201559_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-9255-8-22","volume":"8","author":"AM Miller","year":"2011","unstructured":"Miller AM . Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22.","journal-title":"J Inflamm (Lond)"},{"key":"BFjhh201559_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.322.7285.531","volume":"322","author":"E O'Brien","year":"2001","unstructured":"O'Brien E, Waeber B, Parati G, Staessen J, Myers MG . Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322: 531\u2013536.","journal-title":"BMJ"},{"key":"BFjhh201559_CR14","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/bmj.320.7242.1128","volume":"320","author":"E O'Brien","year":"2000","unstructured":"O'Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA et al. Use and interpretation of Ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128\u20131134.","journal-title":"BMJ"},{"key":"BFjhh201559_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/01.CIR.74.6.1399","volume":"74","author":"P Pignoli","year":"1986","unstructured":"Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R . Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399\u20131406.","journal-title":"Circulation"},{"key":"BFjhh201559_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ndt\/gfl019","volume":"21","author":"P Pauletto","year":"2006","unstructured":"Pauletto P, Rattazzi M . Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 2006; 21: 850\u2013853.","journal-title":"Nephrol Dial Transplant"},{"key":"BFjhh201559_CR17","first-page":"1026","volume":"47","author":"HH Lu","year":"2013","unstructured":"Lu HH, Guo ZR, Hu XS, Wu M, Zhou MH, Zhou ZY . The prospective study of association between C-reactive protein and hypertension in community population. Zhonghua Yu Fang Yi Xue Za Zhi 2013; 47: 1026\u20131030.","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"BFjhh201559_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/08037051.2012.745226","volume":"22","author":"M Zhang","year":"2013","unstructured":"Zhang M, Wang G, Wang A, Tong W, Zhang Y . Association of hypertension with coexistence of abnormal metabolism and inflammation and endothelial dysfunction. Blood Press 2013; 22: 151\u2013157.","journal-title":"Blood Press"},{"key":"BFjhh201559_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jama.2009.943","volume":"302","author":"O Melander","year":"2009","unstructured":"Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstr\u00f6m G et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49\u201357.","journal-title":"JAMA"},{"key":"BFjhh201559_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0895-7061(03)00566-1","volume":"16","author":"KC Sung","year":"2003","unstructured":"Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429\u2013433.","journal-title":"Am J Hypertens"},{"key":"BFjhh201559_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/00004872-200105000-00004","volume":"19","author":"LE Bautista","year":"2001","unstructured":"Bautista LE, L\u00f3pez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI . Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857\u2013861.","journal-title":"J Hypertens"},{"key":"BFjhh201559_CR22","first-page":"CR570","volume":"13","author":"M Ozdogan","year":"2007","unstructured":"Ozdogan M, Bozcuk H, Coban E . Low-grade inflammation in white-coat hypertension. Med Sci Monit 2007; 13: CR570\u2013CR573.","journal-title":"Med Sci Monit"},{"key":"BFjhh201559_CR23","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","volume":"290","author":"HD Sesso","year":"2003","unstructured":"Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM . C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945\u20132951.","journal-title":"JAMA"},{"key":"BFjhh201559_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/01.HYP.0000146691.51307.84","volume":"44","author":"L Niskanen","year":"2004","unstructured":"Niskanen L, Laaksonen DE, Nyyss\u00f6nen K, Punnonen K, Valkonen VP, Fuentes R et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859\u2013865.","journal-title":"Hypertension"},{"key":"BFjhh201559_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1055\/s-0033-1348880","volume":"22","author":"M Peer","year":"2013","unstructured":"Peer M, Boaz M, Zipora M, Shargorodsky M . Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors. Int J Angiol 2013; 22: 223\u2013228.","journal-title":"Int J Angiol"},{"key":"BFjhh201559_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MBP.0b013e3283651d19","volume":"18","author":"O Turak","year":"2013","unstructured":"Turak O, \u00d6zcan F, Canpolat U, I\u015fleyen A, Cebeci M, \u00d6ks\u00fcz F et al. Increased echocardiographic epicardial fat thickness and high-sensitivity CRP level indicate diastolic dysfunction in patients with newly diagnosed essential hypertension. Blood Press Monit 2013; 18: 259\u2013264.","journal-title":"Blood Press Monit"},{"key":"BFjhh201559_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jash.2011.03.004","volume":"5","author":"MS Amer","year":"2011","unstructured":"Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM . Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens 2011; 5: 395\u2013400.","journal-title":"J Am Soc Hypertens"},{"key":"BFjhh201559_CR28","first-page":"97","volume":"22","author":"V Gupta","year":"2011","unstructured":"Gupta V, Sachdeva S, Khan AS, Haque SF . Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi J Kidney Dis Transpl 2011; 22: 97\u2013103.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"BFjhh201559_CR29","first-page":"298","volume":"12","author":"A Parlak","year":"2012","unstructured":"Parlak A, Aydo\u011fan U, Iyisoy A, Dikililer MA, Kut A, Cak\u0131r E et al. Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg 2012; 12: 298\u2013304.","journal-title":"Anadolu Kardiyol Derg"},{"key":"BFjhh201559_CR30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5543\/tkda.2013.20025","volume":"41","author":"E B\u00fcy\u00fckkaya","year":"2013","unstructured":"B\u00fcy\u00fckkaya E, Karaka\u015f MF, Kurt M, Motor S, Ak\u00e7ay AB, B\u00fcy\u00fckkaya S et al. The serum pentraxin-3 is elevated in patients with cardiac syndrome X. Turk Kardiyol Dern Ars 2013; 41: 290\u2013295.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"BFjhh201559_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/gerona\/glq030","volume":"65","author":"Y Yano","year":"2010","unstructured":"Yano Y, Matsuda S, Hatakeyama K, Sato Y, Imamura T, Shimada K et al. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010; 65: 547\u2013552.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BFjhh201559_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/147323001003800106","volume":"38","author":"HE Ataoglu","year":"2010","unstructured":"Ataoglu HE, Yilmaz F, Uzunhasan I, Cetin F, Temiz L, D\u00f6venta\u015f YE et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res 2010; 38: 52\u201361.","journal-title":"J Int Med Res"},{"key":"BFjhh201559_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2796.2012.02548.x","volume":"272","author":"A Schiopu","year":"2012","unstructured":"Schiopu A, Hedblad B, Engstr\u00f6m G, Struck J, Morgenthaler NG, Melander O . Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med 2012; 272: 484\u2013491.","journal-title":"J Intern Med"},{"key":"BFjhh201559_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20071868","volume":"205","author":"AM Miller","year":"2008","unstructured":"Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339\u2013346.","journal-title":"J Exp Med"},{"key":"BFjhh201559_CR35","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","volume":"114","author":"YS Choi","year":"2009","unstructured":"Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117\u20133126.","journal-title":"Blood"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201559","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:45:48Z","timestamp":1647542748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,4]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFjhh201559"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2015.59","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,4]]},"assertion":[{"value":"1 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}